277 related articles for article (PubMed ID: 9536273)
1. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.
Andreansky S; He B; van Cott J; McGhee J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Gene Ther; 1998 Jan; 5(1):121-30. PubMed ID: 9536273
[TBL] [Abstract][Full Text] [Related]
2. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.
Parker JN; Gillespie GY; Love CE; Randall S; Whitley RJ; Markert JM
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2208-13. PubMed ID: 10681459
[TBL] [Abstract][Full Text] [Related]
3. Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice.
Broberg EK; Peltoniemi J; Nygårdas M; Vahlberg T; Röyttä M; Hukkanen V
J Virol; 2004 Dec; 78(23):13139-52. PubMed ID: 15542666
[TBL] [Abstract][Full Text] [Related]
4. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene.
Benedetti S; Dimeco F; Pollo B; Cirenei N; Colombo BM; Bruzzone MG; Cattaneo E; Vescovi A; Didonato S; Colombo MP; Finocchiaro G
Hum Gene Ther; 1997 Jul; 8(11):1345-53. PubMed ID: 9295129
[TBL] [Abstract][Full Text] [Related]
5. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
Toda M; Martuza RL; Kojima H; Rabkin SD
J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551
[TBL] [Abstract][Full Text] [Related]
6. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma.
Wong RJ; Patel SG; Kim S; DeMatteo RP; Malhotra S; Bennett JJ; St-Louis M; Shah JP; Johnson PA; Fong Y
Hum Gene Ther; 2001 Feb; 12(3):253-65. PubMed ID: 11177562
[TBL] [Abstract][Full Text] [Related]
7. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.
Hellums EK; Markert JM; Parker JN; He B; Perbal B; Roizman B; Whitley RJ; Langford CP; Bharara S; Gillespie GY
Neuro Oncol; 2005 Jul; 7(3):213-24. PubMed ID: 16053696
[TBL] [Abstract][Full Text] [Related]
8. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors.
Ram Z; Walbridge S; Heiss JD; Culver KW; Blaese RM; Oldfield EH
J Neurosurg; 1994 Mar; 80(3):535-40. PubMed ID: 8113867
[TBL] [Abstract][Full Text] [Related]
9. Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-gamma.
Kanno H; Hattori S; Sato H; Murata H; Huang FH; Hayashi A; Suzuki N; Yamamoto I; Kawamoto S; Minami M; Miyatake S; Shuin T; Kaplitt MG
Cancer Gene Ther; 1999; 6(2):147-54. PubMed ID: 10195881
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.
Markert JM; Cody JJ; Parker JN; Coleman JM; Price KH; Kern ER; Quenelle DC; Lakeman AD; Schoeb TR; Palmer CA; Cartner SC; Gillespie GY; Whitley RJ
J Virol; 2012 May; 86(9):5304-13. PubMed ID: 22379082
[TBL] [Abstract][Full Text] [Related]
11. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.
Miyatake S; Martuza RL; Rabkin SD
Cancer Gene Ther; 1997; 4(4):222-8. PubMed ID: 9253507
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
13. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.
Chambers R; Gillespie GY; Soroceanu L; Andreansky S; Chatterjee S; Chou J; Roizman B; Whitley RJ
Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1411-5. PubMed ID: 7877992
[TBL] [Abstract][Full Text] [Related]
14. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.
Andreansky SS; He B; Gillespie GY; Soroceanu L; Markert J; Chou J; Roizman B; Whitley RJ
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11313-8. PubMed ID: 8876132
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.
Jarnagin WR; Zager JS; Klimstra D; Delman KA; Malhotra S; Ebright M; Little S; DeRubertis B; Stanziale SF; Hezel M; Federoff H; Fong Y
Cancer Gene Ther; 2003 Mar; 10(3):215-23. PubMed ID: 12637943
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer.
Wei MX; Tamiya T; Hurford RK; Boviatsis EJ; Tepper RI; Chiocca EA
Hum Gene Ther; 1995 Apr; 6(4):437-43. PubMed ID: 7612701
[TBL] [Abstract][Full Text] [Related]
18. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector.
Herrlinger U; Kramm CM; Aboody-Guterman KS; Silver JS; Ikeda K; Johnston KM; Pechan PA; Barth RF; Finkelstein D; Chiocca EA; Louis DN; Breakefield XO
Gene Ther; 1998 Jun; 5(6):809-19. PubMed ID: 9747461
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.
Reisoli E; Gambini E; Appolloni I; Gatta V; Barilari M; Menotti L; Malatesta P
Cancer Gene Ther; 2012 Nov; 19(11):788-95. PubMed ID: 22996742
[TBL] [Abstract][Full Text] [Related]
20. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
